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ungi, including both yeasts and many moulds (Zygomycetes
eing a major exception). Detection of 1,3-beta, D-glucan
s approved for clinical use though cost and technical issues
ave limited its clinical acceptance for routine use. These
ethods are aimed at providing non-invasive and rapid
ethods for establishing a diagnosis of these often lethal
nfections.
oi:10.1016/j.ijid.2010.02.2194
urden of Plasmodium vivax malaria in Latin Amer-
ca (Invited Presentation)
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pidemiology of P. vivax Malaria in the World and Latin
merica
.J. Rodriguez-Morales
Universidad Central de Venezuela, Caracas, DC, Venezuela
Morbidity and mortality burden of malaria, particu-
arly in children, represents a public health threat also in
hose countries from regions such as South East Asia and
atin America with moderate to low levels of transmis-
ion. Between them epidemiological patterns are similar,
ower malaria inoculation rates sustained with a predom-
nant prevalence of Plasmodium vivax infection. Malaria
ortality in these areas has been mainly attributed to P.
alciparum, but its direct and indirect burden has not well
eﬁned. These patterns are increasingly causing concern
n some countries. Globally, ∼250 million clinical episodes
ccur annually (2.7 in Latin America); most of these are
aused by infection with P. falciparum and P. vivax. Although
. falciparum is justiﬁably regarded as the greater menace
ecause of its high mortality, widespread antimalarial drugs
esistance and its dominance on Africa, malaria due to P.
ivax has also placed signiﬁcant burdens on health, longevity
nd general prosperity of large sections of the human pop-
lation. The debilitating impact of P. vivax malaria remains
igh, unacceptable and preventable for well over one billion
nhabitants of the planet. Complicated and even fatal cases
f malaria due to P. vivax have been increasingly reported
n the medical literature. Plasmodium vivax can cause both
equestration-related and non-sequestration-related com-
lications of severe malaria, including cerebral malaria,
enal failure, circulatory collapse, severe anemia, abnormal
leeding, ARDS and jaundice. In Latin America the burden of
ortality due to malaria, although decreasing, is still signiﬁ-
ant. Powerful antimalarial campaigns in the region directed
ainly to P. falciparum achieved a signiﬁcant reduction of
ortality in the last century. Evidence suggests that P. vivax
an imposes a signiﬁcant burden of mortality that may have
esulted from its interaction with other diseases and con-
itions. These and other epidemiological issues are herein
iscussed at a global level and focused in Latin America.
oi:10.1016/j.ijid.2010.02.2195
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olecular Epidemiology of P. vivax: tools for Malaria Con-
rol
. Escalante
Arizona State University, Tempe, AZ, USA
Plasmodium vivax is the most prevalent human malarial
arasite in several areas of Asia and South-Central America.
lthough Plasmodium genomics is improving our knowledge
f the organism’s complex biology, population-based inves-
igations are needed to explore the extent of the parasites’
enetic variation, how the observed variation is geograph-
cally distributed, and how such diversity affects or can
e used to assess the success of control measures. Unfor-
unately, the lack of suitable in vitro culturing methods
or P. vivax imposes the use of ﬁeld specimens for popu-
ation studies. Such circumstances have limited molecular
pidemiologic and genetic diversity studies to a handful of
ntigens and few genetic markers that could be considered
eutral, that is, that are not expected to be under natu-
al selection by the immune response or antimalarial drugs.
irst, I will discuss the emerging patterns on the genetic
iversity of P. vivax using neutral markers and explore
he value of comparative approaches to assess potential
ntigenic regions using closely related Plasmodium species
ound inmacaques. I will show an example with genes encod-
ng a well known antigen, AMA-1. Then, I will review the
urrent status of our knowledge on the genetic diversity of
his parasite in Latin-America. Overall, P. vivax populations
n the new world have low levels of genetic diversity and
ndergo clonal expansions. Such low genetic polymorphism
hould be considered while using genetic markers in epi-
emiologic investigations that aim to assess, for example,
he frequency of recrudescent infections or the reintroduc-
ion/expansion of the parasite in a given geographic area in
he context of control efforts.
oi:10.1016/j.ijid.2010.02.2196
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evere and complicated Malaria due to P. vivax
. Murillo
University of Miami, Miami, FL, USA
NO ABSTRACT RECEIVED
oi:10.1016/j.ijid.2010.02.2197
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reatment, Prophylaxis and Resistance in P. vivax Malaria
. Torres
Tropical Medicine Institute, Caracas, Venezuela
The burden of malaria caused by Plasmodium vivax
emains under-appreciated to a great extent, both in terms
f its clinical spectrum and incidence of disease. Con-
rol measures are hampered by both the emergence of
hloroquine (CQ) resistance and the presence of dormant
ypnozoite stages in the liver, which result in relapse infec-
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tions weeks after the cure of the initial episode. Although
CQ remains the ﬁrst line of treatment for patients with vivax
malaria in most of the world, CQ monotherapy is now vir-
tually ineffective in Papua Indonesia with signiﬁcant clinical
resistance apparent throughout the Indonesian archipelago.
Sporadic cases have been reported from South America and
Asia. Unfortunately, the mechanism of P. vivax CQ resistance
is largely unknown and as yet no genetic markers have been
identiﬁed.
Since clinical studies are difﬁcult to carry out in this
species due to factors such as individual variations in patient
immune status, reinfections and frequent relapses, and in
vitro susceptibility assays applicability is limited by lack of
culture methods, the global prevalence of CQ resistance to
P. vivax continues to be poorly deﬁned.
Primaquine, an 8-aminoquinoline compound, is the only
commercially available drug with hypnozoitocidal activity
against P. vivax and is widely used for terminal prophy-
laxis; yet, little is known about how the drug works, if it
works, or how it fails. Reports of true PQ failure and subse-
quent P. vivax relapse are unusual. Most suspected cases can
be ascribed to poor patient adherence. The lack of effec-
tive alternatives to PQ against hypnozoites represents an
important drawback in clinical practice andmay be as opera-
tionally crippling to control efforts against P. vivax, as having
no access to insecticides, bed nets, reliable diagnostics, or
chemoprophylaxis.
Plasmodium vivax malaria will linger as a persistent
and severe challenge to public health as long as our
drug armamentarium remains limited and substantial areas
of our knowledge on its biology, epidemiology, genetics,
metabolism, and mechanisms of resistance to antimalarials,
remain obscure.
doi:10.1016/j.ijid.2010.02.2198
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Mixed infection of inﬂuenza A viruses is common
Y. Furuse1,∗, A. Suzuki1, N. Nukiwa2, N. Fuji 1, H. Oshitani1
1 Tohoku University Graduate School of Medicine, Sendai,
Japan
2 Tohoku University School of Medicine, Sendai, Japan
Background: Reassortment, which is the rearrangement
of viral gene segments in a host cell infected with two
different viruses, is an important mechanism for the evo-
lution of inﬂuenza viruses. A mixed infection of more than
one virus could lead to reassortment. To better understand
the occurrence of quasispecies in one host, we investigated
mixed infection in individual isolates for seasonal inﬂuenza
A viruses using amantadine sensitivity as a marker.
Methods: We cultured viruses with amantadine, and per-
formed sequencing, RFLP, cloning, and quantitative PCR to
detect mixed population in clinical samples.Results: Culturing with amantadine shows evidence of a
high number of mixed populations. When sensitive isolates,
whose M genes were in a certain lineage, were cultured in
medium with amantadine, the viruses with M genes from
a different lineage appeared after several passages. In con-
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rast, the other assays can hardly detect mixed populations.
he proportion of minor viruses in the mixed population may
e too small to be identiﬁed by these assays. We showed
considerably higher proportion (at least 6/11) of mixed
opulations in analyzed samples.
Conclusion: The existence of quasispecies in each isolate
s common. However, the proportion of these, which can be
ess than 1%, is too low to be detected by conventional meth-
ds. Such mixed populations, in which reassortment occurs,
ay have a signiﬁcant role in the evolution of viruses.
oi:10.1016/j.ijid.2010.02.2199
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nﬂuenza vaccine delivery to adolescents: Assessment of
wo multicomponent interventions
.M. Gargano1,∗, K. Pazol2, J.E. Painter3, J.M. Sales3,
. Murray4, C. Morfaw5, L.M. Jones3, P. Weiss3, W.A.
renstein6, R.J. DiClemente3, J.M. Hughes1
Emory University, Atlanta, GA, USA
Centers for Disease Control and Prevention, Atlanta, GA,
SA
Emory University, Rollins School of Public Health, Atlanta,
A, USA
Medical College of Georgia, Department of Pediatric Infec-
ious Disease, Augusta, GA, USA
Richmond County Health Department, Augusta, GA, USA
Bill and Melinda Gates Foundation, Seattle, WA, USA
Background: Despite efforts to enhance inﬂuenza vac-
ination among persons at highest risk of complications,
nﬂuenza remains a health burden in the United States.
vidence indicates that vaccination of elementary school
hildren protects them from inﬂuenza, and reduces trans-
ission. However, there are no published intervention trials
emonstrating the impact of strategies designed to enhance
nﬂuenza vaccination rates speciﬁcally among adolescents.
Objective: Assessing the efﬁcacy of twomulti-component
nterventions designed to enhance inﬂuenza vaccination
ates among adolescents attending middle- and high-schools
n three rural counties in Georgia, U.S.A.
Methods: This study employs a non-randomized, three-
rmed controlled design across 2 years. The three arms
onsist of: 1) a multi-component school-based inﬂuenza
accination intervention condition (County 1), 2) a multi-
omponent provider-based inﬂuenza vaccination condition
County 2), and 3) a standard of care condition (County
). The multi-component interventions each consisted of
structural component (school-based or provider-based
rovision of inﬂuenza vaccination) and an educational com-
onent (a brochure and a school skit), designed to enhance
accine education among adolescents and their parents.
Results: During the 2008 to 2009 inﬂuenza season in
ounty 1, there were 70 students vaccinated out of 370 stu-
ents (18.9%). During the same year in County 2, there were
10 out of 736 students vaccinated (14.9%). In the ﬁrst year,
tudents in County 1 were 25% more likely to be vaccinated
han students in County 2 (RR = 1.26, 95% CI: 0.96-1.66). Dur-
ng the current 2009-2010 inﬂuenza season, in County 1 we
ave vaccinated 114 out of 375 students (30.4%), a 62.2%
ncrease from the previous inﬂuenza vaccination season.
